Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Inventiva S.A.

Inventiva Contemplates The End Of The Road

The group’s MASH candidate lanifibranor carries hefty sales forecasts but Inventiva might run out of cash before the approval trial reports.

Clinical Trials Commercial

Bangers In MASH: How Rezdiffra's Rivals Stack Up

A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.

Clinical Trials Liver & Hepatic

No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration

US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.

Approvals Liver & Hepatic

Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration

As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).

Liver & Hepatic Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Molecular Diversity
  • Other Names / Subsidiaries
    • Inventiva Pharmaceuticals
UsernamePublicRestriction

Register